Literature DB >> 19141059

Systemic treatment of anti-CD4CD25 T cell monoclonal antibody exacerbates sialoadenitis in submandibular glands during the early life in lupus-prone female NZB x NZWF mice.

Toshiharu Hayashi1, Chie Adachi, Keiko Hasegawa.   

Abstract

BACKGROUND: The maintenance mechanisms of peripheral tolerance by CD4(+)CD25(+) T cells before the development of sialoadenitis in secondary Sjögren's syndrome (sSS) are not well understood. The aim of the present study is to examine the effect of reduction of CD4(+)CD25(+) T cells on the development of sialoadenitis during the early life in female NZB x NZWF(1) (B/WF(1)) mice, a model for human sSS.
METHODS: Female B/WF(1) mice at 3 days after birth were treated with either anti-mouse CD4(+)CD25(+) T cells rat IgG(1) monoclonal antibody (mAb) or Rat IgG(1)(control). At 25 weeks of age, autoantibodies against nucleus and cytoplasm of ductal epithelial and myoepithelial cells, and histpathology of submandibular glands were examined in the mAb-treated and control groups. Also the development of anti-Ro/SS-A antibodies was examined until 25 weeks of age in both groups.
RESULTS: The mAb-treated group showed severe lesions with the development of autoantibodies compared to the control group.
CONCLUSIONS: The present results suggest that peripheral CD4(+)CD25(+) T cells may, at least in part, contribute to down-regulate the development of sialoadenitis in submandibular glands of lupus-prone female B/WF(1) mice during their early life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19141059     DOI: 10.1111/j.1600-0714.2008.00730.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

Review 1.  The NZB/W F1 mouse model for Sjögren's syndrome: A historical perspective and lessons learned.

Authors:  Harini Bagavant; Aleksandra Michrowska; Umesh S Deshmukh
Journal:  Autoimmun Rev       Date:  2020-10-22       Impact factor: 9.754

2.  Destruction of salivary and lacrimal glands by Th1-polarized reaction in a model of secondary Sjögren's syndrome in lupus-prone female NZB × NZWF(1) mice.

Authors:  Toshiharu Hayashi; Natsumi Shimoyama; Takuya Mizuno
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

Review 3.  Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2010-08-17

Review 4.  Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2011-06-01

Review 5.  Sjögren's syndrome: studying the disease in mice.

Authors:  Nicolas Delaleu; Cuong Q Nguyen; Ammon B Peck; Roland Jonsson
Journal:  Arthritis Res Ther       Date:  2011-06-13       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.